Bleomycin HCl 中文名称: 盐酸博来霉素

别名: Bleomycin hydrochloride; 67763-87-5; DTXSID2042690; SCHEMBL21331830;

目录号: V40820 纯度: ≥98%

COA 产品数据产品说明书 SDS

Bleomycin HCl 是一种 DNA 损伤剂，可以抑制 DNA 合成。

Bleomycin HCl CAS号: 67763-87-5
产品类别: New2

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
5mg
10mg
25mg
50mg
100mg
500mg
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

Other Forms of Bleomycin HCl:

硫酸博莱霉素

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

Bleomycin HCl 是一种 DNA 损伤剂，可以抑制 DNA 合成。 Bleomycin HCl 是一种抗肿瘤抗生素。

生物活性&实验参考方法

靶点	DNA/RNA Synthesis
体外研究 (In Vitro)	博来霉素诱导的 DNA 损伤最常见的类型是单链和双链断裂以及单个脱硫连接点/脱硫开关的短路。博来霉素是一种真正的拟放射化合物，可模拟电离辐射的遗传效应[1]。盐酸博莱霉素对UT-SCC-19A细胞系的IC50值为4.0±1.3 nM。 UT-SCC Bleomycin HydroHClide (50, 100 μM; 24, 48)-12A和UT-SCC-12B均对博来霉素具有较强的耐药性； IC50值分别为14.2±2.8nM和13.0。 ±1.1 nM[2]。 h) 诱导 RLE-6TN 细胞 (50 μM) 和 A549 细胞 (100 μM) 肺纤维化 [4]。
体内研究 (In Vivo)	盐酸博莱霉素可用于动物建模，产生动物肺纤维化模型。第0天用盐酸博莱霉素(3.5-4.0mg/kg；气管内注射剂)治疗后，第4天体重下降，随后第7天盐酸博来霉素(3.5-4.0mg/kg；气管内注射剂)增加；气管内制剂）可显着增加肺动脉高压浓度并增加右尾叶质量[3]。滴注； 5.0 mg/kg/天）使 80 只体重约为 20-30 g 的 8 周龄美容 BALB/c 大鼠产生肺纤维化。博莱霉素诱导 α-SMA 和胶原蛋白 I 表达水平 [4] 盐酸博来霉素（气管内；2.5 mg/kg；1.25 mg/mL，每只小鼠约 50 μl）产生玩具 C57BL/6 模型（8 周龄，平均体重约24.5克）肺纤维化[5]。
细胞实验	ADIPO-P2细胞在37°C、5% CO2气氛下在D-MEM高葡萄糖培养基中培养，补充有20%胎牛血清、青霉素(100 U/mL)和链霉素( 100 微克/毫升）。 1.5 × 105 细胞/mL 在 TC25 Corning 烧瓶中作为单层培养。每个实验设置两个烧瓶：一个用于处理的培养物，另一个用于对照。 ADIPO-P2 细胞在对数生长期暴露于 2.5 μg/mL 硫酸博来霉素脉冲 30 分钟。作为对照的平行培养物不接受硫酸博莱霉素。硫酸博莱霉素暴露的持续时间和浓度是根据我们实验室在哺乳动物细胞中进行的使用硫酸博莱霉素暴露的早期研究来选择的。硫酸博莱霉素脉冲处理完成后，用汉克平衡盐溶液洗涤两次，然后用新鲜培养基维持细胞培养直至收获。处理后，细胞连续培养五次或传代。当培养物达到汇合（大约 4 × 105 细胞/mL 培养基）时，进行传代培养。继代培养时，通过胰蛋白酶消化收集细胞，并通过用 0.4% 台盼蓝染色约 200 μL 的等分试样来确定活细胞的数量。该过程可以估计细胞生长。随后，将细胞悬浮在新的培养基中，并以1×1055细胞/mL的密度添加到新鲜的培养瓶中继续生长。处理结束后，剩余的细胞要么被扔掉，要么转移到另一个烧瓶中进行细胞遗传学分析，该分析在 18 小时零 10 天后进行。在培养的最后三个小时将秋水仙碱 (0.1 μg/mL) 添加到细胞培养物中以分析染色体畸变。制备染色体时遵循标准方案。收获后，细胞经历低渗休克，固定在 3:1 甲醇:乙酸溶液中，铺在载玻片上，然后进行 PNA-FISH 处理。进行了两个单独的实验。
动物实验	动物/疾病模型：雄性Fischer 344大鼠，8-10周龄，体重150-250克[3] 剂量：3.5-4毫克/千克给药途径：气管内实验结果：第4天体重下降，第7天体重增加，实验终止。
药代性质 (ADME/PK)	吸收、分布和排泄全身吸收率约为45%。据报道，中度至重度肾功能衰竭患者尿液中排泄的剂量不足20%。硫酸博来霉素几乎不经胃肠道吸收，必须通过肠外途径给药。博来霉素经胸膜腔内或腹膜腔内给药后可全身吸收。据报道，胸膜腔内给药后博来霉素的全身吸收率为45%。肌内注射（IM）、皮下注射（SC）、腹膜腔内注射（IP）或胸膜腔内注射（IPL）后，博来霉素可迅速吸收，并在30至60分钟内达到血浆峰浓度。肌注和皮下注射后，博来霉素的全身生物利用度分别为 100% 和 70%，而腹腔注射和腹膜后注射的全身生物利用度均为 45%，与静脉注射和推注给药相比。博来霉素广泛分布于全身，静脉推注 15 单位/平方米后，患者的平均分布容积为 17.5 升/平方米。博来霉素的蛋白结合率极低 (1%)。有关博来霉素（共 9 项）的更多吸收、分布和排泄（完整）数据，请访问 HSDB 记录页面。代谢/代谢物肝脏生物转化尚不清楚；可能通过组织中的酶促降解（基于动物研究）。组织酶活性存在差异，这可能决定博来霉素的毒性和抗肿瘤作用……目前尚不清楚其代谢产物是否具有活性。博来霉素由胞质半胱氨酸蛋白酶——博来霉素水解酶灭活。该酶广泛分布于正常组织中，但皮肤和肺除外，而皮肤和肺正是博来霉素毒性的靶器官。通过酶促降解进行全身药物清除可能仅在肾功能严重受损的患者中才较为重要。生物半衰期 115分钟对于肌酐清除率超过35 mL/分钟的患者，博来霉素的血清或血浆终末半衰期约为2小时。对于肌酐清除率低于 35 mL/分钟的患者，药物的终末半衰期与肌酐清除率呈负相关。接受每日 30 单位博来霉素持续输注 4-5 天的患者，其血浆中博来霉素的平均稳态浓度约为 150 ng/mL，且与血浆蛋白的结合量极低。博来霉素在血浆中的清除呈双相性；初始半衰期约为 1.3 小时，终末半衰期约为 9 小时。
毒性/毒理 (Toxicokinetics/TK)	药物相互作用既往接受过博来霉素治疗的患者使用全身麻醉可能导致肺功能迅速恶化，因为博来霉素会使肺组织对氧敏感；即使吸入氧浓度被认为安全，术后仍可能发生肺纤维化。同时使用抗肿瘤药物或放射疗法可能增加博来霉素的毒性，包括骨髓抑制（博来霉素单独使用很少引起骨髓抑制）以及黏膜和肺毒性…… 顺铂引起的肾功能损害可能导致博来霉素清除延迟，即使是低剂量也可能导致博来霉素毒性；由于这两种药物经常联合使用，因此建议谨慎用药。接受博来霉素和长春碱（无论是否联合顺铂）治疗的患者以及少数单独接受博来霉素治疗的患者均出现过雷诺现象。顺铂引起的低镁血症可能是接受博来霉素和顺铂联合化疗方案的患者发生雷诺现象的另一个相关因素，尽管并非必要因素。然而，这些病例中雷诺现象的病因尚不明确，可能与基础疾病或血管受损、博来霉素、长春碱、低镁血症或这些因素的某种组合有关。一名28岁男性，患有生殖细胞癌，在接受博来霉素和依托泊苷化疗期间发生急性心肌梗死。在接受肝素和阿司匹林治疗后，患者的心电图未见Q波，且恢复顺利。梗死发生4周后，铊-201心肌显像仅显示一处小的、不可逆的后间隔灌注缺损；未进行冠状动脉造影。化疗方案继续进行，并调整为依托泊苷、顺铂和异环磷酰胺，心脏症状或心电图变化均未复发。
参考文献	[1]. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49. [2]. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4. [3]. Therapeutic administration of inhaled INS1009, a LRX-15 prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103. [4]. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185. [5]. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11(11):978.
其他信息	治疗用途抗生素，抗肿瘤药；抗生素，糖肽类；抗代谢药，抗肿瘤药博来霉素适用于治疗头颈部（包括口腔、舌、扁桃体、鼻咽、口咽、鼻窦、腭、唇、颊黏膜、牙龈、会厌、喉和喉旁）、宫颈、阴茎、皮肤和外阴的鳞状细胞癌。它也适用于治疗睾丸癌（包括胚胎性细胞癌、绒毛膜癌和畸胎瘤）、食管癌和甲状腺癌。/美国产品标签包含/ 博来霉素适用于治疗霍奇金淋巴瘤和非霍奇金淋巴瘤。 /美国产品标签包含/ 博来霉素适用于治疗艾滋病相关卡波西肉瘤。/美国产品标签不包含/ 有关博来霉素（共12种）的更多治疗用途（完整）数据，请访问HSDB记录页面。药物警告博来霉素最严重的毒性反应是肺部反应，通常表现为间质性肺炎，约10%的用药患者会出现这种情况。博来霉素肺炎有时会进展为肺纤维化，并导致约1%的用药患者死亡。肺毒性通常与剂量和年龄相关，最常发生于70岁以上的患者以及总剂量超过400单位的患者；然而，肺毒性难以预测，据报道，年轻患者即使接受较低剂量（例如总剂量低于 200 单位）也会出现肺毒性。一位老年患者仅接受了 20 单位的博来霉素治疗，就发生了致命性肺纤维化。罕见情况下，在持续输注博来霉素期间，曾有报道出现突发性急性胸痛综合征，提示胸膜心包炎。降低药物输注速度可改善此综合征，患者可能需要镇痛药治疗疼痛；停药后通常可完全康复。至少有一例患者在接受含博来霉素的联合治疗后出现与肉芽肿相关的空洞性肺结节；尽管继续治疗，这些病变仍自行消退。接受博来霉素治疗的患者需要密切监测临床表现和肺毒性迹象。对于出现肺毒性的患者，可能需要调整剂量或停药。有关博来霉素（共28条）的更多药物警告（完整）数据，请访问HSDB记录页面。药效学博来霉素是一种抗生素，已被证实具有抗肿瘤活性。博来霉素选择性抑制脱氧核糖核酸（DNA）的合成。鸟嘌呤和胞嘧啶的含量与丝裂霉素诱导的交联程度相关。在高浓度药物下，细胞RNA和蛋白质的合成也会受到抑制。体外研究表明，博来霉素可抑制B细胞、T细胞和巨噬细胞的增殖，并损害抗原呈递以及干扰素γ、TNFα和IL-2的分泌。除了博来霉素（主要作用于 G2 期和 M 期）外，其他抗生素抗肿瘤药物均不具有细胞周期特异性。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C55H84CLN17O21S3
分子量	1451.00476741791
精确质量	1449.487
CAS号	67763-87-5
相关CAS号	Bleomycin sulfate;9041-93-4
PubChem CID	456190
外观&性状	White to light yellow solid powder
LogP	-7.5
tPSA	685
氢键供体(HBD)数目	20
氢键受体(HBA)数目	31
可旋转键数目(RBC)	36
重原子数目	96
分子复杂度/Complexity	2580
定义原子立体中心数目	18
SMILES	CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H](C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
InChi Key	OYVAGSVQBOHSSS-QRQYLRPSSA-O
InChi Code	InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41?,42-,43-,53+,54-/m0/s1
化学名	3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
别名	Bleomycin hydrochloride; 67763-87-5; DTXSID2042690; SCHEMBL21331830;
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意：请将本产品存放在密封且受保护的环境中（例如氮气保护），避免吸湿/受潮和光照。
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	H2O : ~100 mg/mL DMSO : ~50 mg/mL
溶解度 (体内实验)	配方 1 中的溶解度: ≥ 2.5 mg/mL (Infinity mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。配方 2 中的溶解度:* ≥ 2.5 mg/mL (Infinity mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。 20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。 View More* 配方 3 中的溶解度: ≥ 2.5 mg/mL (Infinity mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。配方 4 中的溶解度: 100 mg/mL (Infinity mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶 (<60°C). 请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

H2O : ~100 mg/mL
DMSO : ~50 mg/mL

溶解度 (体内实验)

配方 1 中的溶解度: ≥ 2.5 mg/mL (Infinity mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

配方 2 中的溶解度: ≥ 2.5 mg/mL (Infinity mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (Infinity mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

配方 4 中的溶解度: 100 mg/mL (Infinity mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶 (<60°C).

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	0.6892 mL	3.4459 mL	6.8918 mL
	5 mM	0.1378 mL	0.6892 mL	1.3784 mL
	10 mM	0.0689 mL	0.3446 mL	0.6892 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
CTID: NCT03407144
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-11-20

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
CTID: NCT03033914
Phase: Phase 1/Phase 2 Status: Active, not recruiting
Date: 2024-11-20

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
CTID: NCT05008224
Phase: Phase 2 Status: Completed
Date: 2024-11-20

GISEL:Registry of Breast Cancer Patients Treated With ECT
CTID: NCT06683404
Phase: Status: Completed
Date: 2024-11-12

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
CTID: NCT03712202
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-11-06

View More

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
CTID: NCT04685616
Phase: Phase 3 Status: Recruiting
Date: 2024-10-30

Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study
CTID: NCT06189092
Phase: Status: Recruiting
Date: 2024-10-29

The Effect of Reduced Bleomycin in Electrochemotherapy Treatment
CTID: NCT06647342
Phase: Phase 4 Status: Not yet recruiting
Date: 2024-10-17

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
CTID: NCT04638790
Phase: Phase 3 Status: Recruiting
Date: 2024-09-27

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
CTID: NCT01873326
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-07-03

FIL Study on ABVD DD-DI as Upfront Therapy in HL.
CTID: NCT03159897
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-06-28

Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
CTID: NCT06437158
Phase: Phase 2 Status: Recruiting
Date: 2024-06-03

Investigating Cardiovascular Adverse Events Related to Cancer Treatment
CTID: NCT03199300
Phase: Status: Recruiting
Date: 2024-05-17

HD21 for Advanced Stages
CTID: NCT02661503
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-05-13

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
CTID: NCT03755804
Phase: Phase 2 Status: Recruiting
Date: 2024-04-04

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
CTID: NCT01712490
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-02-20

Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
CTID: NCT01347294
Phase: Phase 4 Status: Active, not recruiting
Date: 2023-11-07

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
CTID: NCT00352027
Phase: Phase 2 Status: Completed
Date: 2023-09-22

Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
CTID: NCT05327309
Phase: N/A Status: Completed
Date: 2023-09-13

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
CTID: NCT01390584
Phase: Phase 2 Status: Terminated
Date: 2023-06-29

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
CTID: NCT00003389
Phase: Phase 3 Status: Completed
Date: 2023-06-29

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
CTID: NCT02429687
Phase: Phase 3 Status: Recruiting
Date: 2023-04-25

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
CTID: NCT02429700
Phase: Phase 3 Status: Recruiting
Date: 2023-04-25

Bleomycin Jet Injections in Keloids
CTID: NCT04582305
Phase: Phase 4 Status: Unknown status
Date: 2022-11-09

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
CTID: NCT02292979
Phase: Phase 2 Status: Completed
Date: 2022-08-19

Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
CTID: NCT05395962
Phase: Phase 2 Status: Recruiting
Date: 2022-05-27

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
CTID: NCT02582697
Phase: Phase 3 Status: Unknown status
Date: 2021-11-29

Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts
CTID: NCT05023408
Phase: Phase 2 Status: Completed
Date: 2021-08-26

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
CTID: NCT02298283
Phase: Phase 2 Status: Completed
Date: 2021-07-26

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
CTID: NCT00577993
Phase: Phase 3 Status: Completed
Date: 2020-11-16

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
CTID: NCT00006916
Phase: Phase 2 Status: Terminated
Date: 2020-10-26

Electrochemotherapy for Non-curable Gastric Cancer
CTID: NCT04139070
Phase: Phase 1 Status: Unknown status
Date: 2020-08-20

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
CTID: NCT02784054
Phase: Phase 2 Status: Unknown status
Date: 2020-03-19

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
CTID: NCT00654732
Phase: Phase 2 Status: Completed
Date: 2020-02-28

Bleomycin Infusion (MMP®) to Repigment Achromic Scars
CTID: NCT04046679
Phase: Phase 4 Status: Unknown status
Date: 2019-08-06

Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
CTID: NCT00993512
Phase: Phase 1 Status: Completed
Date: 2019-04-29

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
CTID: NCT00038558
Phase: Phase 3 Status: Completed
Date: 2018-10-31

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
CTID: NCT00369681
Phase: Phase 2 Status: Completed
Date: 2018-08-27

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
CTID: NCT00136565
Phase: Phase 2 Status: Completed
Date: 2018-08-23

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
CTID: NCT00135499
Phase: Phase 3 Status: Terminated
Date: 2018-08-23

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
CTID: NCT00026208
Phase: Phase 2 Status: Completed
Date: 2018-07-24

The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
CTID: NCT03477448
Phase: Phase 4 Status: Unknown status
Date: 2018-03-26

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
CTID: NCT01659099
Phase: Phase 3 Status: Terminated
Date: 2018-03-07

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
CTID: NCT03018626
Phase: Phase 3 Status: Unknown status
Date: 2017-07-28

Electrochemotherapy on Head and Neck Cancer
CTID: NCT02549742
Phase: Phase 2 Status: Unknown status
Date: 2017-01-18

Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
CTID: NCT02782754
Phase: Phase 2 Status: Unknown status
Date: 2016-05-25

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
CTID: NCT01251107
Phase: Phase 3 Status: Completed
Date: 2015-08-13

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
CTID: NCT01060904
Phase: Phase 1 Status: Completed
Date: 2014-12-18

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
CTID: NCT00225173
Phase: Phase 2 Status: Terminated
Date: 2014-08-27

Dose Escalating Study for Amphinex-based PCI of Bleomycin.
CTID: NCT01872923
Phase: Phase 1 Status: Completed
Date: 2014-06-16

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
CTID: NCT02161692
Phase: Phase 2 Status: Completed
Date: 2014-06-12

Electrochemotherapy as a Palliative Treatment for Brain Metastases
CTID: NCT01322100
Phase: Phase 1 Status: Terminated
Date: 2013-07-31

Rituximab and ABVD for Hodgkin's Patients
CTID: NCT00504504
Phase: Phase 2 Status: Completed
Date: 2013-07-09

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
CTID: NCT01404936
Phase: Phase 2 Status: Completed
Date: 2013-02-01

HD12 for Advanced Stages
CTID: NCT00265031
Phase: Phase 3 Status: Completed
Date: 2012-06-25

Prospective Study on HIV-related Hodgkin Lymphoma
CTID: NCT01468740
Phase: Phase 2 Status: Unknown status
Date: 2011-11-09

Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy
CTID: NCT00918593
Phase: Phase 2 Status: Withdrawn
Date: 2011-09-27

HD11 fo
Electrochemotherapy versus narrow excision margins for high-risk, primary cutaneous melanoma
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2020-04-03

ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2019-04-17

Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2019-01-24

A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck 'UPSTREAM'
CTID: null
Phase: Phase 2 Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2017-10-05

A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL).
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2017-07-17

UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
CTID: null
Phase: Phase 3 Status: GB - no longer in EU/EEA
Date: 2017-04-05

Electrochemotherapy versus standard radiatiotherapy for the treatment of basal cell carcinoma
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2016-09-12

SEQUENTIAL THERAPY WITH VEMURAFENIB AND ELECTROCHEMOTHERAPY FOR IN-TRANSIT MELANOMA METASTASES: A MULTICENTER SINGLE ARM PHASE II CLINICAL PROSPECTIVE STUDY OF THE ITALIAN MELANOMA INTERGROUP (IMI)
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2016-05-17

Endoscopic assisted electrochemotherapy in addition to neoadjuvant treatment of locally advanced rectal cancer: a randomized clinical phase II trial.
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2016-05-12

Endoscopic electroporation in esophageal cancer
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2016-03-23

PHASE II STUDY OF INTRAOPERATIVE ELECTROCHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE PANCREATIC CANCER
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2016-03-18

Open, randomized, with two parallel treatment groups combined therapy
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2015-06-02

Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma
CTID: null
Phase: Phase 2 Status: Completed
Date: 2015-05-04

A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2015-02-26

A multicenter study to evaluate a risk-adapted strategy for treatment of extra cranial non seminomateous malignant germ cell tumour in children, adolescent and young adult
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2014-10-23

Treatment of Inoperable Colorectal Cancer with
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-07-02

Clinical trial to evaluate the efficacy and tolerability of electrochemotherapy for palliative treatment in patients with head and neck squamous cell carcinoma
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2014-02-12

Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.
CTID: null
Phase: Phase 3 Status: Prematurely Ended
Date: 2013-09-26

Electrochemotherapy of Head and Neck Cancer
CTID: null
Phase: Phase 2 Status: Completed
Date: 2013-09-11

Effect of chemotherapy on endothelial function in patients with testicular cancer
CTID: null
Phase: Phase 4 Status: Completed
Date: 2013-02-18

A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin Lymphoma
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2012-11-15

An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and neck squamous cell carcinoma unsuitable for surgery and radiotherapy
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2012-01-27

An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients with Cutaneous Breast Cancer Metastases
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2011-10-17

HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET
CTID: null
Phase: Phase 3 Status: Completed
Date: 2011-10-14

Electrochemotherapy versus conventional surgery in treatment of basal cell carcinoma
CTID: null
Phase: Phase 4 Status: Completed
Date: 2010-07-21

A phase II multi-centre study of MBVD in elderly and/or cardiopathic patients affected by Hodgkin s lymphoma (HL).
CTID: null
Phase: Phase 2 Status: Completed
Date: 2010-03-30

EFFICACY OF ELETTROPORATION COMBINED WITH BLEOMYCIN IN THE TREATMENT OF KELOIDS AND HYPERTROPHIC SCARS: A PILOT STUDY
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2009-12-15

A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT)
CTID: null
Phase: Phase 4 Status: GB - no longer in EU/EEA
Date: 2009-08-20

HD16 for early stages in Hodgkins Lymphoma
CTID: null
Phase: Phase 3 Status: Completed
Date: 2009-07-09

PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKINS LYMPHOMA.
CTID: null
Phase: Phase 3 Status: Prematurely Ended
Date: 2009-07-03

Palliative treatment of ulcerated cutaneous metastases: Randomised trial between electrochemotherapy and radiotherapy
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2009-05-29

Early salvage with high dose chemotherapy and stem cell transplantation in advanced stage Hodgkins lymphoma patients with positive positron emission tomography after two courses of ABVD (PET-2 positive) and comparison of radiotherapy versus no radiotherapy in PET-2 negative patients.
CTID: null
Phase: Phase 3 Status: Completed
Date: 2008-10-20

PHASE II MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION IN PTS WITH HIGH-RISK HODGKIN LYMPHOMA, IDENTIFIED AS FDG-PET SCAN POSITIVE AFTER TWO CONVENTIONAL ABVD COURSES
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2008-06-20

HD18 for advanced stages in Hodgkins Lymphoma
CTID: null
Phase: Phase 3 Status: Completed
Date: 2008-04-17

A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma
CTID: null
Phase: Phase 3 Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2008-04-09

Phase II Trial for the Treatment of Advanced Classical Kaposis Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy
CTID: null
Phase: Phase 2 Status: Completed
Date: 2007-07-27

Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI
CTID: null
Phase: Phase 2 Status: Ongoing, Completed
Date: 2007-06-20

A phase II study about the use of intensified hybrid chemotherapy regimen ChLVVP/ABVVP in advanced Hodgkin lymphoma patients.
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2006-12-29

A CLINICO-PATHOLOGIC STUDY OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA
CTID: null
Phase: Phase 2 Status: Completed
Date: 2006-12-12

The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma.
CTID: null
Phase: Phase 3 Status: Completed
Date: 2006-08-15

PROTOCOL FOR THE TREATMENT OF EXTRACRANIAL GERM CELL TUMOURS
CTID: null
Phase: Phase 4 Status: Completed
Date: 2006-06-23

A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer
CTID: null
Phase: Phase 3 Status: Completed
Date: 2006-03-23

A risk-adapted strategy of the use of dose-dense chemotherapy
CTID: null
Phase: Phase 3 Status: Completed
Date: 2005-10-25

TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2005-02-25

Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma
CTID: null
Phase: Phase 3 Status: Completed
Date: